Danese D - Search Results

1

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.

Obici L, Ajroud-Driss S, Lin KP, Berk JL, Gillmore JD, Kale P, Koike H, Danese D, Aldinc E, Chen C, Vest J, Adams D; HELIOS-A Collaborators Study Group. Obici L, et al. Among authors: danese d. Neurol Ther. 2023 Oct;12(5):1759-1775. doi: 10.1007/s40120-023-00522-4. Epub 2023 Jul 31. Neurol Ther. 2023. PMID: 37523143 Free PMC article.

2

Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H. Merkel M, et al. Among authors: danese d. Expert Opin Pharmacother. 2023 May-Aug;24(10):1205-1214. doi: 10.1080/14656566.2023.2215925. Epub 2023 May 26. Expert Opin Pharmacother. 2023. PMID: 37219406

3

Estimating health state utilities in primary hyperoxaluria type 1: a valuation study.

de Freitas HM, Danese D, Hubig L, Lloyd A, Lombardelli S. de Freitas HM, et al. Among authors: danese d. J Med Econ. 2023 Jan-Dec;26(1):386-393. doi: 10.1080/13696998.2023.2176678. J Med Econ. 2023. PMID: 36852648 Free article.

4

Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.

Danese D, Goss D, Romano C, Gupta C. Danese D, et al. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1. BMC Nephrol. 2023. PMID: 37884879 Free PMC article.

5

Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study.

Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Yang H, Moritz ML. Wang X, et al. Among authors: danese d. Front Med (Lausanne). 2021 Sep 20;8:703305. doi: 10.3389/fmed.2021.703305. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34616753 Free PMC article.

6

Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.

Sas DJ, Mara K, Mehta RA, Seide BM, Banks CJ, Danese DS, McGregor TL, Lieske JC, Milliner DS. Sas DJ, et al. Among authors: danese ds. Pediatr Nephrol. 2024 Jan;39(1):141-148. doi: 10.1007/s00467-023-06074-x. Epub 2023 Jul 17. Pediatr Nephrol. 2024. PMID: 37458799 Free PMC article.

7

Luteinizing hormone (LH) levels in male workers exposed to urban stressors.

Tomao E, Tomei G, Rosati MV, Caciari T, Danese D, Gamberale D, Vacca D, Palermo P, Anzelmo V, Tomei F. Tomao E, et al. Among authors: danese d. Sci Total Environ. 2009 Aug 1;407(16):4591-5. doi: 10.1016/j.scitotenv.2009.05.009. Epub 2009 May 27. Sci Total Environ. 2009. PMID: 19477485

8

Coexistence of a parathyroid adenoma and parathyroid cyst causing primary hyperparathyroidism.

Ardito G, Fadda G, Danese D, Modugno P, Giordano A, Revelli L, Ardito F, Pontecorvi A. Ardito G, et al. Among authors: danese d. J Endocrinol Invest. 2003 Jul;26(7):679-82. doi: 10.1007/BF03347029. J Endocrinol Invest. 2003. PMID: 14594122

9

Cloning of the mouse insulin receptor substrate-3 (mIRS-3) promoter, and its regulation by p53.

Sciacchitano S, Orecchio A, Lavra L, Misiti S, Giacchini A, Zani M, Danese D, Gurtner A, Soddu S, Di Mario U, Andreoli M. Sciacchitano S, et al. Among authors: danese d. Mol Endocrinol. 2002 Jul;16(7):1577-89. doi: 10.1210/mend.16.7.0881. Mol Endocrinol. 2002. PMID: 12089352

10

Gargano L, Mentuccia D, Conti L, Viceconti N, Sibilla R, Danese D, Celi FS, Gandolfo G, Centanni M. Gargano L, et al. Among authors: danese d. Horm Res. 2001;56(5-6):172-6. doi: 10.1159/000048114. Horm Res. 2001. PMID: 11910203

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page